Member Info for crumbs

Possible we will soon get news on ImmunoBody nano delivery....amazing to think next year ImmunoBody could Reval itself to be the perfect combo partner for keytruda a drug that Merck has made it's number one focus.with many rivals that is certainly a hot area.

That right that SCIB2 trial will be over by H1 next year? 'The manufacturing development for SCIB2 is expected to start in Q2 2018 ahead of expected commencement of a toxicology study in Q4 2018 and completion of the study in H1 2019. ' Though I'm not happy with the inabillity of team Chippers to get is even one small commercial tie up before having to go to market for a raising team Lindy makes up for it.... 3 trials in 5 cancer types and data next year! For baby bio like this that is quite remarkable and a hit on any will be game-changing .... still feel modi 1 at least will get partnered before it goes to trial and the amazing always appearing yet then always then disappearing 4th target in that planned trial will reappear for good!... SCIB2 could gain more targets if CRUK feel positive with it too... go on team scancell and Chippers pull your 2 million shares finger out!

Mines gone March 8th.. hopefully, scancell will give us all an extra one this year :)

Could well do but doubt for long...and if so I'll nibble a few of those ones too.

Well I'm taking up mine for the reason of supporting team science scancell by taking up my OO I am financially contributing to the progress of that work and it is that work which will (hopefully) bring me as an investor a big reward down the line so for me makes sense to support my own investment...plus it is about treating cancer patients and defeating this beast that can affect us all.

I think the main thing is if they do license a trial would be a fast affair... again it would be very late-stage disease patients so rather conclusive results would be soon in.

Not sure...that is your job! :)

Though I think SCIB1 combo in 25 patients ought to be fully covered by this raising: Therapeutic drug development is a long process and the Directors believe that the Company will require additional funding in order to complete the aforementioned SCIB1 clinical study and Modi-1 study. The timing of the aforementioned studies are also subject to, inter alia, timely regulatory approval. Additional funding could be provided either by a commercial agreement with a development partner, such as a large pharmaceutical company, or by further equity issuance to existing and/or new Shareholders. The Directors believe that delivering the milestones outlined above will enhance the value of the Company and prepare it for further later stage fundraising. The Directors also believe that these milestones will ensure wider recognition of the Company both in the US and Europe for the quality and value of both the ImmunoBody� and Moditope� platforms.

Indeed and the possibility of another PTM platform and also uses beyond cancer... the IP here is massive we just need the means to unlock it all

ISA deal... I would expect if we get a deal with BioNtech we would get the same kind of one ISA have from us: Under the terms of this agreement, ISA has granted Scancell an exclusive worldwide license to manufacture, develop and commercialise the AMPLIVANT�:Modi-1 conjugate therapy and will contribute know-how and expertise related to AMPLIVANT�. Clinical studies will be conducted by Scancell and are expected to commence in H1 2019. In return, ISA will receive an upfront payment from Scancell and is entitled to milestone and royalty fees following achievement of certain criteria as defined in the agreement. Financial details were not disclosed.

No, the BioNtech deal would be more a case of they licence modi 1 for TCR probably not for a huge initial amount per target but they then would pay for trials and we would get probably get small milestone payments but then a cut on commercial success that would hopefully be a quite attractive cut

Yes, I think so though we are licensing their product we do not know how much it costs I reckon there is some deal where they would get a cut on commercialisation as we need them they need us so the licencing amount is probably not huge as it is in both our interests for clinical success....least that's my thinking on it :)

This raising and fact modi 1 is being manufactured puts pressure on anyone wanting in on it... can they afford wait hmm probably!

ISA is a vital tie up due to the adjuvant... so we need them and I suppose they need us lol... It will be interesting if we get some more of that I'm thinking the nanovesicle delivery for ImmunoBody I'm very intrigued about that and hope we hear more and maybe get a tie-up with a third party there too.

I know... what can I say...I'm supposing patent is key... I'm not happy with 12p price of raising and the size of dilution when we were pushing to 20p and although its great that JC has loads of shares to entice him into getting the best for us all it grates the price and way he has got them... anyways to counterbalance it our IP just increased with the new platform coming into scancell...Immunotherapy may well be the new internet but is he a Larry Page

Indeed from the placing RNS: 'The Company is continuing discussions on potential commercial partnership discussions for the Moditope� platform alongside its clinical development plans, with multiple partnering discussions in progress.' I like the multiple part

Might have been GF toying :)

Face it the CRUK and BioNtech tie ups have come from Lindy's relationships with other scientists it took KF himself to make a move to be involved in combo trial...The old men have done nothing to progress Lindy's work to commercialization lest not yet.

Not sure about that probably a cash raising on the way there.

On the hunt for deals: Emma Walmsley continues her R&D metamorphosis at GlaxoSmithKline with another new big new hire in the guise of Kevin Sin, an ex-Genentech executive who will be seeking out new pipeline plays for the U.K.�s largest drugmaker. Sin will become SVP and head of worldwide business development for pharmaceuticals R&D. Translation: Sin will be on the hunt for pipeline deals, or, as GSK puts it: �[He] will play a critical role in strengthening GSK�s pharmaceutical pipeline and identifying enabling technologies to enhance delivery of innovative new medicines for patients.� He�ll join in July after leaving Roche�s major biologics arm Genentech, where he is VP and global head of oncology business development, responsible for partnering, acquisition and licensing activities for novel oncology therapeutics. He�ll be based in San Francisco. https://www.fiercebiotech.com/biotech/hunt-for-r-d-deals-gsk-raids-roche-s-exec-cupboard-again Even fairly locally base to our San Diego desk